Xilio Therapeutics (XLO) Other Accumulated Expenses (2020 - 2026)

Xilio Therapeutics has disclosed Other Accumulated Expenses across 7 years of filings, most recently posting $198000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $198000.0, up 17.86% year-over-year; the trailing twelve-month figure through Mar 2026 was $198000.0 (up 17.86% YoY), and the FY2025 annual result was $83000.0, down 36.64% from the prior year.
• Other Accumulated Expenses came in at $198000.0 for Q1 2026 at Xilio Therapeutics, up from $83000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $264000.0 in Q3 2022 to a low of $28000.0 in Q1 2024.
• The 5-year median for Other Accumulated Expenses is $131000.0 (2024), against an average of $127529.4.
• Across the five-year window, Other Accumulated Expenses plunged 74.45% in 2022 and soared 500.0% in 2025, its largest moves.
• Xilio Therapeutics' Other Accumulated Expenses stood at $82000.0 in 2022, then sank by 41.46% to $48000.0 in 2023, then surged by 172.92% to $131000.0 in 2024, then plunged by 36.64% to $83000.0 in 2025, then jumped by 138.55% to $198000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $198000.0 (Q1 2026), $83000.0 (Q4 2025), and $88000.0 (Q3 2025), per Business Quant data.